Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation AwardZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that...
The article clarifies how to distinguish allergy symptoms from infections and outlines steps to reduce irritation and protect eye health.FLORENCE, Ky., June 2, 2026...
First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...
First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.
August 15, 2025: Update
OTTAWA, ON, Aug. 15, 2025 /CNW/ - This outbreak investigation is ongoing. The public health notice will be updated as the investigation...
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
ORLANDO, Fla., Aug. 13, 2025 /PRNewswire/ -- The national food poisoning law firm of Ron Simon & Associates, along with Orlando-based Newsome Law, PA, has filed...
NORWALK, Conn., Aug. 13, 2025 /PRNewswire/ -- Heartwood Partners, LLC is pleased to announce that Heartwood Partners III, LP ("Fund III") successfully exited its...
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02
LOS...